JPWO2020172485A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020172485A5
JPWO2020172485A5 JP2021549213A JP2021549213A JPWO2020172485A5 JP WO2020172485 A5 JPWO2020172485 A5 JP WO2020172485A5 JP 2021549213 A JP2021549213 A JP 2021549213A JP 2021549213 A JP2021549213 A JP 2021549213A JP WO2020172485 A5 JPWO2020172485 A5 JP WO2020172485A5
Authority
JP
Japan
Prior art keywords
composition
clpp
patient
cancer
imipridone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021549213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520997A (ja
JP2022520997A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019142 external-priority patent/WO2020172485A1/en
Publication of JP2022520997A publication Critical patent/JP2022520997A/ja
Publication of JPWO2020172485A5 publication Critical patent/JPWO2020172485A5/ja
Publication of JP2022520997A5 publication Critical patent/JP2022520997A5/ja
Pending legal-status Critical Current

Links

JP2021549213A 2019-02-22 2020-02-21 イミプリドンを使用する方法 Pending JP2022520997A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962809140P 2019-02-22 2019-02-22
US62/809,140 2019-02-22
US201962908105P 2019-09-30 2019-09-30
US62/908,105 2019-09-30
PCT/US2020/019142 WO2020172485A1 (en) 2019-02-22 2020-02-21 Methods of using imipridones

Publications (3)

Publication Number Publication Date
JP2022520997A JP2022520997A (ja) 2022-04-04
JPWO2020172485A5 true JPWO2020172485A5 (https=) 2023-02-20
JP2022520997A5 JP2022520997A5 (https=) 2023-02-20

Family

ID=72144740

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549213A Pending JP2022520997A (ja) 2019-02-22 2020-02-21 イミプリドンを使用する方法

Country Status (3)

Country Link
US (1) US20220143024A1 (https=)
JP (1) JP2022520997A (https=)
WO (1) WO2020172485A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020228047B2 (en) * 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
EP4337214A4 (en) * 2021-05-13 2025-01-29 Chimerix, Inc. USES AND METHODS FOR RECURRENT PRIMARY CNS NEOPLASMAS
CN115448921B (zh) * 2021-06-08 2023-08-01 四川大学 一类咪唑烷并嘧啶酮化合物及在治疗HsClpP介导的疾病中的用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
WO2024199457A1 (zh) * 2023-03-31 2024-10-03 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
WO2024218275A1 (en) * 2023-04-20 2024-10-24 Institut Gustave Roussy Liquid and solid compositions of imipridone derivatives
WO2025250553A1 (en) * 2024-05-28 2025-12-04 Chimerix, Inc. Solid state forms of imipridone derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925251B2 (en) * 2011-10-19 2018-03-27 President And Fellows Of Harvard College Treatments for Mycobacterium tuberculosis
PL3408298T3 (pl) * 2016-01-29 2025-03-31 Oncoceutics, Inc. Modulacja przez imiprydony receptora sprzężonego z białkiem g (gpcr)
US10172862B2 (en) * 2017-01-30 2019-01-08 Oncoceutics, Inc. Imipridones for gliomas

Similar Documents

Publication Publication Date Title
TWI670074B (zh) 在癌症免疫療法中有用的生物標記
Günther et al. Comparative kinetics of Escherichia coli-and Staphylococcus aureus-specific activation of key immune pathways in mammary epithelial cells demonstrates that S. aureus elicits a delayed response dominated by interleukin-6 (IL-6) but not by IL-1A or tumor necrosis factor alpha
Zhao et al. Staphylococcal enterotoxin M induced inflammation and impairment of bovine mammary epithelial cells
CN113286604B (zh) 治疗炎症性疾病的蛋白质
WO2016016262A1 (en) Methods and compositions for diagnosing and treating inflammatory bowel disorders
US11391740B2 (en) Methods and materials for identifying and treating cancer
JPWO2020172485A5 (https=)
Koh et al. Secreted extracellular cyclophilin A is a novel mediator of ventilator-induced lung injury
Hwang et al. Topical ruxolitinib in the treatment of necrobiosis lipoidica: a prospective, open-label study
Pattabiraman et al. Efficacy of targeted mast cell inhibition therapy in chronic prostatitis/chronic pelvic pain syndrome
Kashiwabara et al. Surgical trauma-induced adrenal insufficiency is associated with postoperative inflammatory responses
AU2021230103A1 (en) Low dose human interleukin-2 for the treatment of amyotrophic lateral sclerosis
US20190376149A1 (en) Ddx43 as a biomarker of resistance to mek1/2 inhibitors
WO2023215834A1 (en) Methods for treating bladder cancer
EP4592404A1 (en) Asah1 as a biomarker for determining the risk for recurrence of glioblastoma multiforme in a subject
CN120405130B (zh) 一种预测结直肠癌化疗敏感的生物标志物及其应用
KR20200083371A (ko) 뇌수막염 진단을 위한 정보제공방법
Altimmime et al. CXCL12, CA15-3, and Liver function Tests as Predictors of Liver Metastasis in Breast Cancer
AU2020288361B2 (en) Treatment and diagnosis of chronic inflammatory conditions in the lower urinary tract
Odah et al. S1999 Is Tramadol a Safer Opioid in IBD? Insights From a Large Propensity-Matched Analysis
Richards et al. S1998 Molecular Differentiation of Guselkumab and Ustekinumab in Moderately to Severely Active Crohn’s Disease: Post Hoc Analysis of the GALAXI 2 and 3 Phase 3 Studies
Odah et al. S2000 Safety of COX-2 Inhibitor NSAIDs in Inflammatory Bowel Disease: A Propensity-Matched Cohort Study Using Real-World Data
Mu et al. Gut microbiota metabolite butyric acid alleviated Klebsiella Pneumoniae induced lung injury by regulating CX3CR1+ NK via PI3K/AKT pathway
US11150237B2 (en) Patient-specific biomarkers of Escherichia coli invasion in inflammatory bowel disease
Sahyoun et al. S2001 Assessment of Sociodemographic Factors and Outcomes of Ulcerative Colitis Hospitalizations: A Large Population-Based Study